RESUMEN
The main treatment goals for chronic obstructive pulmonary disease (COPD) are the reduction of its symptoms and future risks. The addition of the traditional herbal medicine Hochuekkito (TJ-41) treatment to pulmonary rehabilitation (PR) has been reported to improve dyspnea and health-related quality of life (HRQOL) in patients with COPD. However, the reason for this improvement is not sufficiently understood. The purpose of the present study was to investigate whether the addition of TJ-41 treatment to PR improves symptoms of apathy, dyspnea, and HRQOL and increases physical activity among apathetic patients with COPD. Apathetic patients with COPD were randomly assigned to receive low-intensity exercise with (TJ-41 group) or without (control group) TJ-41 treatment for 12 weeks. A total of 29.9% of COPD patients had apathetic symptoms without severe depression. After the 12-week treatment, Apathy Scale, Patient Health Questionnaire-9, visual analog scale for dyspnea, and COPD assessment test energy scores decreased significantly in the TJ-41 group (p < 0.05), but not in the control group. Additionally, the total number of steps taken was significantly higher in the TJ-41 group than in the control group. TJ-41 combined with PR may benefit apathetic patients with COPD with respect to apathy, dyspnea, HRQOL, and physical activity, but larger randomized placebo-controlled trials are required to validate the findings because of the small sample size and lack of placebo controls in this study.
RESUMEN
The molecular mechanisms by which ATP1A1 mutation-mediated cell proliferation or tumorigenesis in aldosterone-producing adenomas (APAs) have not been elucidated. First, we investigated whether the APA-associated ATP1A1 L104R mutation stimulated cell proliferation. Second, we aimed to clarify the molecular mechanisms by which the ATP1A1 mutation-mediated cell proliferated. We performed transcriptome analysis in APAs with ATP1A1 mutation. ATP1A1 L104R mutation were modulated in human adrenocortical carcinoma (HAC15) cells (ATP1A1-mutant cells), and we evaluated cell proliferation and molecular signaling events. Transcriptome and immunohistochemical analysis showed that Na/K-ATPase (NKA) expressions in ATP1A1 mutated APA were more abundant than those in non-functioning adrenocortical adenoma or KCNJ5 mutated APAs. The significant increase of number of cells, amount of DNA and S-phase population were shown in ATP1A1-mutant cells. Fluo-4 in ATP1A1-mutant cells were significantly increased. Low concentration of ouabain stimulated cell proliferation in ATP1A1-mutant cells. ATP1A1-mutant cells induced Src phosphorylation, and low concentration of ouabain supplementation showed further Src phosphorylation. We demonstrated that NKAs were highly expressed in ATP1A1 mutant APA, and the mutant stimulated cell proliferation and Src phosphorylation in ATP1A1-mutant cells. NKA stimulations would be a risk factor for the progression and development to an ATP1A1 mutant APA.
Asunto(s)
Adenoma/patología , Aldosterona/metabolismo , Proliferación Celular , ATPasa Intercambiadora de Sodio-Potasio/genética , Adenoma/metabolismo , Adenoma Corticosuprarrenal/metabolismo , Adenoma Corticosuprarrenal/patología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Citocromo P-450 CYP11B2/genética , Citocromo P-450 CYP11B2/metabolismo , Canales de Potasio Rectificados Internamente Asociados a la Proteína G/genética , Humanos , Mutación , Ouabaína/farmacología , Fosforilación/efectos de los fármacos , Puntos de Control de la Fase S del Ciclo Celular , ATPasa Intercambiadora de Sodio-Potasio/metabolismo , Transcriptoma , Familia-src Quinasas/metabolismoRESUMEN
Purpose Anorexia induced by cytotoxic chemotherapy on delayed phase is a highly frequent adverse event. We aimed to determine the effects of rikkunshito (RKT) on chemotherapy-induced anorexia (CIA) in patients with lung cancer. Methods This prospective, randomized, cross-over pilot trial included 40 lung cancer patients scheduled to undergo cisplatin-based chemotherapy and randomized to either a group given RKT 7.5 g/day for 14 days (Group A, N = 20) or not (Group B, N = 20), then the treatments were switched. All patients received dexamethasone, palonosetron hydrochloride and aprepitant regardless of group assignment. Rescue drugs were allowed as required. The primary and key secondary endpoints were changes in caloric intake and in plasma acylated ghrelin (AG) levels, respectively. Average daily caloric intake during days 3 to 5 was compared with that on day 1 of each course. Results The primary and key secondary endpoints were analyzed in 31 patients (per protocol population) completing the study. Reduction rate of caloric intake was lower in RKT, than in control courses (18% vs. 25%, P = 0.025). Plasma AG levels significantly declined between days 1 and 3 in RKT (12.3 vs. 7.5 fmol/mL, P < 0.001) and control (10.8 vs. 8.6 fmol/mL, P < 0.001) courses. However, those obviously increased to 8.5 fmol/mL (P = 0.025) by day 5 in RKT course but not in control course (7.7 fmol/mL, P = 0.28). Conclusions Rikkunshito could mitigate CIA and ameliorate plasma AG levels during the delayed phase of CDDP-based chemotherapy in lung cancer patients. Clinical trial registration numbers: UMIN000010748.
Asunto(s)
Anorexia/tratamiento farmacológico , Antineoplásicos/efectos adversos , Cisplatino/efectos adversos , Medicamentos Herbarios Chinos/uso terapéutico , Ghrelina/sangre , Neoplasias Pulmonares/tratamiento farmacológico , Fitoterapia , Acilación , Adulto , Anciano , Anorexia/inducido químicamente , Estudios Cruzados , Ingestión de Energía/efectos de los fármacos , Femenino , Humanos , Japón , Neoplasias Pulmonares/sangre , Masculino , Medicina Tradicional , Persona de Mediana Edad , Proyectos Piloto , Resultado del TratamientoAsunto(s)
Antibacterianos/efectos adversos , Antifúngicos/efectos adversos , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inducido químicamente , Deficiencia del Factor V/inducido químicamente , Factor V/inmunología , Neumonía/tratamiento farmacológico , Anciano , Antibacterianos/administración & dosificación , Especificidad de Anticuerpos , Antifúngicos/administración & dosificación , Ceftriaxona/efectos adversos , Cefalosporinas/efectos adversos , Ciprofloxacina/efectos adversos , Sustitución de Medicamentos , Quimioterapia Combinada , Fluoroquinolonas/efectos adversos , Humanos , Levofloxacino/efectos adversos , Masculino , Meropenem/efectos adversos , Micafungina/efectos adversos , Tiempo de Tromboplastina Parcial , Tiempo de ProtrombinaRESUMEN
Chronic obstructive pulmonary disease (COPD) has significant systemic effects, such as weight loss, which affects exercise capacity, health-related quality of life (HRQOL) and survival. The traditional herbal medicine, Hochuekkito (TJ-41), improves the nutritional status and decreases systemic inflammation in patients with COPD. However, to date, the additive effect of TJ-41 on pulmonary rehabilitation (PR) in patients with COPD has not been researched comprehensively. The purpose of the present study was to investigate the efficacy and safety of adding TJ-41 to PR for patients with COPD. Thirty-three malnourished patients with COPD were randomly assigned to receive low-intensity exercise with (TJ-41 group) or without (control group) TJ-41 treatment for 12 weeks. The primary outcome was the change in the 6-min walk distance (6MWD). Secondary outcomes included changes in the body composition, peripheral muscle strength, modified Medical Research Council dyspnea score, visual analog scale (VAS) score for dyspnea, VAS score for fatigue and COPD assessment test (CAT) score. After the 12-week treatment, body weight and percent ideal body weight were significantly increased in the TJ-41 group (P<0.05), but not in the control group. After the 12-week treatment, the modified Medical Research Council dyspnea score, VAS score for dyspnea, VAS score for fatigue and total CAT score decreased significantly in the TJ-41 group (all P<0.05), but not in the control group. There were no significant differences in the 6MWD and peripheral muscle strength between baseline and after 12 weeks of treatment in either group. No adverse effects were noted with the use of TJ-41. It was concluded that the addition of TJ-41 to PR may benefit malnourished patients with COPD with respect to dyspnea and HRQOL.
Asunto(s)
Lesión Pulmonar Aguda/inducido químicamente , Lesión Pulmonar Aguda/diagnóstico , Enfermedades Pulmonares Intersticiales/inducido químicamente , Enfermedades Pulmonares Intersticiales/diagnóstico , Lesión Pulmonar Aguda/epidemiología , Lesión Pulmonar Aguda/terapia , Amiodarona/efectos adversos , Antiarrítmicos/efectos adversos , Antiinfecciosos/efectos adversos , Antineoplásicos/efectos adversos , Antirreumáticos/efectos adversos , Biomarcadores/sangre , Pruebas de Provocación Bronquial , Diagnóstico por Imagen , Medicamentos Herbarios Chinos/efectos adversos , Pruebas Hematológicas , Humanos , Inmunosupresores/efectos adversos , Interferones/efectos adversos , Japón/epidemiología , Enfermedades Pulmonares Intersticiales/epidemiología , Enfermedades Pulmonares Intersticiales/terapia , Activación de Linfocitos , Factores de Riesgo , Índice de Severidad de la EnfermedadRESUMEN
Recent studies suggest that plasminogen activator inhibitor-1 (PAI-1), a major inhibitor of the fibrinolytic system, may promote the development of asthma. To further investigate the significance of PAI-1 in the pathogenesis of asthma and determine the possibility that PAI-1 could be a therapeutic target for asthma, this study was conducted. First, PAI-1 levels in induced sputum (IS) from asthmatic subjects and healthy controls were measured. In asthmatic subjects, IS PAI-1 levels were elevated, compared with that of healthy controls, and were significantly higher in patients with long-duration asthma compared with short-duration asthma. PAI-1 levels were also found to correlate with IS transforming growth factor-ß levels. Then, acute and chronic asthma models induced by ovalbumin were established in PAI-1-deficient mice and wild-type mice that received intra-airway administrations of small interfering RNA against PAI-1 (PAI-1-siRNA). We could demonstrate that eosinophilic airway inflammation and airway hyperresponsiveness were reduced in an acute asthma model, and airway remodeling was suppressed in a chronic asthma model in both PAI-1-deficient mice and wild-type mice that received intra-airway administration of PAI-1-siRNA. These results indicate that PAI-1 is strongly involved in the pathogenesis of asthma, and intra-airway administration of PAI-1-siRNA may be able to become a new therapeutic approach for asthma.
Asunto(s)
Asma/prevención & control , Inhibidor 1 de Activador Plasminogénico/genética , Interferencia de ARN , ARN Interferente Pequeño/uso terapéutico , Remodelación de las Vías Aéreas (Respiratorias)/genética , Animales , Asma/patología , Bronquitis/prevención & control , Líquido del Lavado Bronquioalveolar/química , Evaluación Preclínica de Medicamentos , Femenino , Factor de Crecimiento de Hepatocito/metabolismo , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Terapia Molecular Dirigida , Ovalbúmina , Inhibidor 1 de Activador Plasminogénico/metabolismo , Eosinofilia Pulmonar/patología , Eosinofilia Pulmonar/prevención & control , ARN Interferente Pequeño/administración & dosificación , Esputo/metabolismoRESUMEN
OBJECTIVES: To evaluate the effect of bakumondoto, Kampo medicine, on cough in patients with chronic obstructive pulmonary disease (COPD). DESIGN: A 16-week, randomized, open-labeled, cross-over design. SETTING: Outpatient clinics at one university hospital and two general hospitals in Japan from May 2007 to March 2009. PARTICIPANTS: Twenty-four elderly patients (14 men and 9 women aged over 65) with COPD. INTERVENTION: Treatment with or without bakumondoto for 8 weeks in a cross-over design. MEASUREMENTS: The primary outcome measurements were the frequency and intensity of cough assessed by a visual analogue scale (VAS) and a daily cough diary. Secondary outcome measurements were quality of life (QOL) assessed using St. George's Respiratory Questionnaire (SGRQ) and lung functions measured using spirometry. RESULTS: Treatment with bakumondoto significantly improved cough severity during the first treatment period (week 0 vs. week 8, p=0.004) and showed a trend to decrease during the second treatment period (week 8 vs. week 16, p=0.129) assessed by the VAS. Neither QOL nor lung function was affected by the treatment with bakumondoto. CONCLUSION: Bakumondoto may be effective in suppressing cough in elderly patients with COPD. To further confirm the efficacy, a larger and placebo-controlled study with objective cough assessment is necessary.